Companies › Chugai Pharmaceutical
6 active drug programs in 6 registered trials: 5 Phase 1, 1 Phase 2; Oncology, Hematology, Gastroenterology; next expected readout Mar 2027.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| DONQ52 | – | Phase 2 | Celiac Disease | Jun 2027 |
| RAY121 Classical complement pathway inhibitor | – | Phase 1 | Antiphospholipid Syndrome (APS) | Mar 2027 |
| ROSE12 | – | Phase 1 | Solid Tumor | Oct 2027 |
| ALPS12 CD20/CD3 bispecific antibody | – | Phase 1 | Extensive Stage Small Cell Lung Cancer | Sep 2028 |
| AUBE00 Mechanism unclear | – | Phase 1 | Solid Tumors | Dec 2029 |
| AQUA07 | – | Phase 1 | ALK Positive Non-small Cell Lung Cancer | Aug 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06371417 | RAY121 | Phase 1 | Antiphospholipid Syndrome (APS) | Hematology | Mar 2027 |
| NCT07239336 | DONQ52 | Phase 2 | Celiac Disease | Gastroenterology | Jun 2027 |
| NCT05907980 | ROSE12 | Phase 1 | Solid Tumor | Oncology | Oct 2027 |
| NCT07107490 | ALPS12 | Phase 1 | Extensive Stage Small Cell Lung Cancer | Oncology | Sep 2028 |
| NCT07030959 | AUBE00 | Phase 1 | Solid Tumors | Oncology | Dec 2029 |
| NCT07617337 | AQUA07 | Phase 1 | ALK Positive Non-small Cell Lung Cancer | Oncology | Aug 2030 |
No annotated target.
–
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.